Skip to content

Exploring the therapeutic effect and mechanism of Lactobacillus rhamnosus Prosci-109 on sarcopenia in the elderly

Exploring the therapeutic effect and mechanism of Lactobacillus rhamnosus Prosci-109 on sarcopenia in the elderly

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400080241
Enrollment
Unknown
Registered
2024-01-24
Start date
2024-01-26
Completion date
Unknown
Last updated
2024-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia

Interventions

Group 1:Lactobacillus rhamnosus prosci-109
Group 2:Placebo

Sponsors

Weihai Municipal Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age =65 years old; 2.In line with the 2019 Asian Working Group on Sarcopenia (AWGS) diagnostic criteria for sarcopenia; 3.The patient has clear consciousness and can complete the examination operation, questionnaire survey and medical history collection by himself or with the help of his family; 4.Agree to participate in this study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Suffering from acute diseases; Severe liver or kidney disease; Severe depression; Patients with a history of severe cerebral infarction, myocardial infarction, cancer, or long-term bed rest due to fractures; 2. Patients who need to take immunosuppressive drugs for a long time or take antibiotics within 1 month before enrollment and take antibiotics during the follow-up period; 3. Those who stopped taking or adjusted the test samples at will during the follow-up period; 4.Patients taking defecation-promoting drugs, such as polyethylene glycol electrolytes, phenolphthalein tablets, and senna leaves, at the same time during the follow-up period; 5. Patients with chronic digestive system diseases or tumors, such as peptic ulcer, inflammatory bowel disease, severe liver disease, etc.; 6. Those who are allergic to the test sample or have obvious gastrointestinal symptoms such as intolerance; 7. Patients with irregular eating habits and great changes during the follow-up period.

Design outcomes

Primary

MeasureTime frame
Limb muscle mass;Strength;Power;Calf circumference measurement;

Secondary

MeasureTime frame
Depression;Anxiety;Sleep;Constipation;cognitive;

Countries

China

Contacts

Public ContactZhang Jinbiao

Weihai Municipal Hospital

drzhangjinbiao@163.com+86 186 6037 8456

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026